| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 58.5 | 37.7 | 45.0 |
| Other income | 0.8 | 0.4 | 0.3 |
| Total income | 59.2 | 38.2 | 45.3 |
| Profit before exceptional items & tax | -5.1 | -9.1 | 0.9 |
| Profit before tax | -5.1 | -9.1 | 0.9 |
| Net profit | -5.0 | -7.1 | 0.5 |
| Operating margin | -8.6% | -23.8% | 2.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +30.00% |
|---|
BSE results filing, NSE: NATCAPSUQ. Figures extracted from the filing.
Natural Capsules Ltd: key numbers
- Share price
- ₹169.52
- Market cap
- ₹176.5 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -8.2×Sector 50.4×
- Promoter holding
- 50.92%-0.12% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Annual General Meeting
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Fund Raise of ₹10.01 Cr
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
- Value
- ₹10.01 Cr
Natural Capsules Investor Presentation: Key Takeaways
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Q1 FY27 Results: Net Loss of ₹5.7 Cr, Loss Widens
Natural Capsules Ltd reported revenue from operations of ₹48.7 Cr (+7.7% YoY) and a net loss of ₹5.7 Cr for Q1 FY27.
- Key figure
- Net loss ₹5.7 Cr
Natural Capsules Earnings Call: Key Takeaways
Natural Capsules Ltd reported Q4 FY26 revenue of ₹58.45cr (up 55% QoQ). Full-year FY26 revenue grew 11% to ₹187.20cr, though the company posted a net loss of ₹24.66cr.
Natural Capsules Earnings Call: Key Takeaways
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.